c-Kit

Inhibitory Selectivity

Catalog No.	Inhibitor Name	c-Kit	Other
A10290	Dasatinib	***	Abl,Src
A10468	Imatinib Mesylate	**	PDGFR,v-Abl
A10996	Cabozantinib	***	VEGFR2/KDR,c-Met,VEGFR3/FLT4
A10103	Axitinib	****	VEGFR1/FLT1,VEGFR2/Flk1,VEGFR2/KDR
A10699	Pazopanib HCl	*	VEGFR1,VEGFR2,VEGFR3
A11411	Dovitinib	****	FLT3,FGFR1,VEGFR3/FLT4
A10967	Vatalanib 2HCl	*	VEGFR2/KDR,VEGFR1/FLT1,VEGFR2/Flk1
A10558	Masitinib	*	Lyn B,PDGFRα,PDGFRβ
A10101	Tivozanib	**	VEGFR2,VEGFR3,EphB2
A10610	Amuvatinib	***	PDGFRα (V561D),FLT3 (D835Y)
A10608	Motesanib Diphosphate	***	VEGFR1,VEGFR2,VEGFR2/Flk1
A10679	OSI-930	**	FLT1,KDR,CSF-1R
A10502	Ki8751	**	VEGFR2,PDGFRα,FGFR2
A10903	Telatinib	****	VEGFR3,VEGFR2,PDGFRα
A11518	Pazopanib	*	VEGFR1,VEGFR2,VEGFR3
A10198	Dovitinib Dilactic Acid	****	FLT3,FGFR1,VEGFR3/FLT4
A16320	Dasatinib Monohydrate	***	Abl ,Src
A14156	AZD2932	***	PDGFRβ,Flt3,VEGFR-2
A10880	Sunitinib Malate		FLT3,PDGFRβ,VEGFR2
A15062	DCC-2618	***	PDGFRα, PDGFRβ
A15519	PLX647	***	Fms
A15520	Pexidartinib (PLX3397)	***	CSF-1R, Flt-3

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Quick View
Imatinib (Gleevec)

Catalog No. A10259
Quick View

添加到收藏
PDGFR 抑制剂

Imatinib (Gleevec)是一种多靶点酪氨酸激酶抑制剂，抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6，0.1和0.1 μM。了解更多

Product Citations (6)

Bulk Inquiry Free Sample
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Takafumi Shima, .et al. Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells, Oncol Rep, 2022, 47: 7 PMID: 34738628
- Reiko Watanabe, .et al. Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration, J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- BM Duggan, .et al. RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice, Endocrinology, 2020, May 30;bqaa086 PMID: 32473019
- Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277